Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference November 30, 2018
Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference November 13, 2018
Cocrystal Pharma Reports 2018 Third Quarter Financial Results and Provides Corporate Update November 12, 2018
Cocrystal Pharma Announces Clinical Trial Agreement for Investigator-Initiated Phase 2a Study in Hong Kong of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus October 8, 2018
Cocrystal Pharma Completes Patient Enrollment in Phase 2a Study Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C September 20, 2018
Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update August 9, 2018
Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV June 28, 2018
Cocrystal Pharma Reports 2018 First Quarter Financial Results and Provides Corporate Update May 11, 2018